Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022
Clearside Biomedical (NASDAQ:CLSD) announced participation in three upcoming investor conferences in August 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clearside Biomedical (NASDAQ:CLSD) announced participation in three upcoming investor conferences in August 2022. The events include:
- BTIG Biotechnology Conference: Panel Discussion on August 9 at 10:00 am ET in New York City.
- Wedbush PacGrow Healthcare Virtual Conference: Fireside Chat on August 10 at 8:35 am ET.
- H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference: Panel and Corporate Presentation on August 17 at 11:00 am ET.
Links to live and archived webcasts are available on Clearside's website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following investor conferences in August 2022:
BTIG Biotechnology Conference
Panel Discussion
Tuesday, August 9, 2022 at 10:00 am ET
New York, NY
Wedbush PacGrow Healthcare Virtual Conference
Fireside Chat
Wednesday, August 10, 2022 at 8:35 am ET
H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Panel Discussion and Corporate Presentation
Wednesday, August 17, 2022 at 11:00 am ET
A link to available live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.